March 16, 2017
USPTO favorable to Ceylad
The U.S. Patent and Trademark Office (USPTO) has been favorable to Ceylad for the fourth time for production of Allogenic TCR-Deficient CAR-T cells.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: T cells
January 9, 2017
Celyad’s patent holds up after being challenged by third party
U.S. Patent and Trade Office (USPTO) has decided to uphold Celyad’s U.S. Patent No. 9,181,527, relating to allogeneic human primary…
October 10, 2016
NOXXON: NOX-A12 synergizes with both T cell and NK cell based therapies
NOXXON Pharma N.V. a clinical-stage biopharmaceutical company primarily focused on cancer treatment, announced that it presented data yesterday at the ESMO conference in Copenhagen, Denmark, studying the role of CXCL12 inhibition by NOX-A12 (olaptesed pegol) in tumor stroma spheroids, a preclinical model that mimics the complexity of the tumor microenvironment.